2009
DOI: 10.3171/2008.7.jns08322
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of intracranial aneurysms with the Enterprise stent: a multicenter registry

Abstract: The authors report initial results of the largest series to date in using the Enterprise for intracranial aneurysm treatment. The Enterprise is associated with a high rate of successful navigation and low occurrence of inaccurate stent deployment. The overall morbidity and mortality rates were low; however, caution should be exercised when considering Enterprise deployment in patients with subarachnoid hemorrhage as the authors' experience demonstrated a high rate of associated hemorrhagic complications leadin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

12
145
1

Year Published

2010
2010
2018
2018

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 242 publications
(158 citation statements)
references
References 15 publications
12
145
1
Order By: Relevance
“…Previous studies showed initial complete occlusion rates from 27-73 % [37][38][39][40] in treating aneurysms by stentassisted coiling; compared with these studies, our results appeared moderate (63 % in group A and 44 % in group B). The cases included in the present series were all widenecked and ruptured aneurysms, thus posing a challenge to angiographic occlusion.…”
Section: Discussioncontrasting
confidence: 64%
“…Previous studies showed initial complete occlusion rates from 27-73 % [37][38][39][40] in treating aneurysms by stentassisted coiling; compared with these studies, our results appeared moderate (63 % in group A and 44 % in group B). The cases included in the present series were all widenecked and ruptured aneurysms, thus posing a challenge to angiographic occlusion.…”
Section: Discussioncontrasting
confidence: 64%
“…In the clinical course of 219 aneurysms treated with the Enterprise VRD, 3% of cases demonstrated significant (AE50%) in-stent stenosis or occlusion. 12,13) Delayed thrombotic events occurred in seven cases (3%), and all delayed events were concomitant to cessation of dual-antiplatelet therapy. 12,13) The factors that contribute to the risk of in-stent stenosis are not established, and it is not clear whether ISA is associated with in-stent stenosis or how long dual antiplatelet therapy should be continued in the postoperative period.…”
Section: Discussionmentioning
confidence: 99%
“…The Enterprise stent is retractable after partial deployment. Exact placement is mostly easy but penetration of the small stent cells with a microcatheter can be challenging [8,9,39] . The body of the stent itself is almost invisible under fl uoroscopy [8] .…”
Section: Cells Not Connectedmentioning
confidence: 99%
“…Stent displacement may be encountered if coiling is attempted immediately after deployment. Therefore awaiting stent endothelialization or coiling with a " jailed " microcatheter is recommended [9] . An adverse event unique for the Enterprise is secondary proximal migration if a short stent is deployed into vessel segments with large caliber diff erences [40] .…”
Section: Cells Not Connectedmentioning
confidence: 99%